Wyeth To Re-Submit Viviant This Year, Expects FDA Advisory Review
This article was originally published in The Pink Sheet Daily
Executive Summary
Merged Pfizer/Wyeth will likely have to choose between Viviant and Fablyn.
You may also be interested in...
Japan Paves Way For Pfizer/Wyeth's Viviant To Hit Crowded Osteo Space
The First Subcommittee on New Drugs at Japan's Ministry of Health June 3 recommended six drugs for approval, including Wyeth/Pfizer's Viviant (bazedoxifene), clearing a hurdle for the merged companies' lead selective estrogen reuptake modulator for postmenopausal osteoporosis in Japan's crowded market
Experts Urge More Use Of Evista And Other Drugs To Prevent Breast Cancer
Movement toward a paradigm shift in breast cancer from reactive treatment to prevention could gain support from the long-term results of the Study of Tamoxifen and Raloxifene (STAR) trial
Experts Urge More Use Of Evista And Other Drugs To Prevent Breast Cancer
Movement toward a paradigm shift in breast cancer from reactive treatment to prevention could gain support from the long-term results of the Study of Tamoxifen and Raloxifene (STAR) trial